Sumanta Kumar Pal, M.D.

  • Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research
  • Co-director, Kidney Cancer Program
  • Medical Oncologist

Sumanta Kumar Pal, M.D.

Especialidades clínicas
  • Medical Oncology
Áreas de especialidad
  • Urology and Urologic Oncology
  • Prostate Cancer
  • Bladder Cancer
  • Kidney Cancer
Enfoque de la investigación
  • Urology and Urologic Oncology
Ayuda disponible en varios idiomas
  • Spanish
Sumanta (Monty) Kumar Pal, M.D., is an internationally recognized leader in the area of genitourinary cancers, including kidney, bladder, and prostate cancer. He is co-director of City of Hope's Kidney Cancer Program and is the head of the kidney and bladder cancer disease team at the institution.

Dr. Pal entered college at the age of 13 and began medical school at University of California Los Angeles at the age of 17. After completing his residency training at UCLA, Dr. Pal completed a fellowship program in medical oncology at City of Hope's comprehensive cancer center where he has remained on faculty since 2009.

Over that span of time, he has published more than 300 PubMed cited articles that have been featured in prominent journals including Cancer Discovery, The Journal of Clinical Oncology, Lancet Oncology, Cancer Cell and European Urology.

Dr. Pal holds patents for new drugs currently under development in prostate cancer and also maintains one of the largest portfolios of clinical trials for kidney and bladder cancer research on the West Coast. He developed an integrated program that focuses heavily on collaborations with basic science researchers at Beckman Research Institute of City of Hope and urologists in the Department of Surgery. Ultimately, Dr. Pal’s goal is to stimulate collaborative research across multiple departments in order to discover novel therapeutic approaches for our currently incurable diseases. He has also worked to push the boundaries of personalized medicine in genitourinary cancers with several seminal publications in rare genitourinary cancers that describe unique therapeutic targets. He is the lead investigator on multiple trials, ranging from early phase 1 experiences to late stage phase 3 studies.
Dr. Pal sits on the editorial board for Kidney Cancer and is a reviewer for multiple journals including Lancet Oncology, The Journal of Clinical Oncology, The Journal of Urology, European Urology and many others. Dr. Pal has received grants from the National Institute of Health, the Comprehensive Cancer Network, SWOG Cancer Research Network and multiple other leading entities in support of his formidable research.
  • 2009 - present, Assistant Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
  • 2009 - present, Co-director, Kidney Cancers Program, City of Hope, Duarte, CA
  • Bladder Cancer
  • Kidney Cancer
  • Prostate Cancer
  • Testicular Cancer
  • Urology and Urologic Cancers


1500 East Duarte Road, Duarte, CA, 91010

Obtener instrucciones

Teléfono :  626-256-4673


  • 2003, David Geffen School of Medicine at UCLA, Los Angeles, CA, M.D.
  • 1998, California State University, Los Angeles Early Entrance Program, College in lieu of high school (program initiated at age 13)
  • Magna Cum Laude, B.Sc.

Beca de investigación

  • 2006 -2009, Fellowship in Hematology/Oncology, City of Hope/Harbor-UCLA Medical Center, Los Angeles, CA


  • 2003 -2006, Residency in Internal Medicine, UCLA Medical Center, Los Angeles, CA
  • 2006-present, American Society of Clinical Oncology (ASCO) (2006- present)
  • National Comprehensive Cancer Network Bladder Cancer Committee (2010-present)
  • HER2-Positive Breast Cancer Committee, ASCO (2012-2013)
  • Genitourinary Cancers Committee, ASCO (2013-present )
Ir al Inicio